Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005977 | 0.86 | CYP1A2 (0.33) | SMN1; SMN2MEN1KMT2AALDH1A1PKM | |
| SCHEMBL1007761 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1PKMKDM4EPOLB | |
| SCHEMBL6379773 | 0.84 | ALDH1A1 (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1PKM | |
| SCHEMBL18665244 | 0.81 | NPSR1 (0.35) | SMN1; SMN2MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL1006452 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL1007598 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2MEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL18660603 | 0.72 | HRH2 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL31158519 | 0.71 | MAPK1 (0.39) | SMN1; SMN2MEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL4196385 | 0.69 | LMNA (0.44) | SMN1; SMN2KMT2AALDH1A1PKM | |
| SCHEMBL7005474 | 0.68 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2ANPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | SMN1; SMN2 3616/4885MEN1 1454/4885KMT2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.